Find in Library

The genomic analyses of pediatric acute lymphoblastic leukemia (ALL) subtypes, particularly T-cell and B-cell lineages, have been pivotal in identifying potential therapeutic targets. Typical genomic analyses have directed attention toward the most commonly mutated genes. However, assessing the contribution of mutations to cancer phenotypes is crucial. Therefore, we estimated the cancer effects (scaled selection coefficients) for somatic substitutions in T-cell and B-cell cohorts, revealing key insights into mutation contributions. Cancer effects for well-known, frequently mutated genes like <i>NRAS</i> and <i>KRAS</i> in B-ALL were high, which underscores their importance as therapeutic targets. However, less frequently mutated genes <i>IL7R</i>, <i>XBP1</i>, and <i>TOX</i> also demonstrated high cancer effects, suggesting pivotal roles in the development of leukemia when present. In T-ALL, <i>KRAS</i> and <i>NRAS</i> are less frequently mutated than in B-ALL. However, their cancer effects when present are high in both subtypes. Mutations in <i>PIK3R1</i> and <i>RPL10</i> were not at high prevalence, yet exhibited some of the highest cancer effects in individual T-cell ALL patients. Even <i>CDKN2A</i>, with a low prevalence and relatively modest cancer effect, is potentially highly relevant for the epistatic effects that its mutated form exerts on other mutations. Prioritizing investigation into these moderately frequent but potentially high-impact targets not only presents novel personalized therapeutic opportunities but also enhances the understanding of disease mechanisms and advances precision therapeutics for pediatric ALL.